JP6889493B2 - 脳卒中からの回復のための方法および組成物 - Google Patents

脳卒中からの回復のための方法および組成物 Download PDF

Info

Publication number
JP6889493B2
JP6889493B2 JP2018521382A JP2018521382A JP6889493B2 JP 6889493 B2 JP6889493 B2 JP 6889493B2 JP 2018521382 A JP2018521382 A JP 2018521382A JP 2018521382 A JP2018521382 A JP 2018521382A JP 6889493 B2 JP6889493 B2 JP 6889493B2
Authority
JP
Japan
Prior art keywords
stroke
composition
hours
administration
onset
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018521382A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531961A (ja
JP2018531961A5 (OSRAM
Inventor
ジョン ジャハンガー アラム，
ジョン ジャハンガー アラム，
Original Assignee
イーアイピー ファーマ， エルエルシー
イーアイピー ファーマ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーアイピー ファーマ， エルエルシー, イーアイピー ファーマ， エルエルシー filed Critical イーアイピー ファーマ， エルエルシー
Publication of JP2018531961A publication Critical patent/JP2018531961A/ja
Publication of JP2018531961A5 publication Critical patent/JP2018531961A5/ja
Application granted granted Critical
Publication of JP6889493B2 publication Critical patent/JP6889493B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018521382A 2015-10-26 2016-10-26 脳卒中からの回復のための方法および組成物 Active JP6889493B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562246574P 2015-10-26 2015-10-26
US62/246,574 2015-10-26
PCT/US2016/058804 WO2017075013A1 (en) 2015-10-26 2016-10-26 Methods and compositions for recovery from stroke

Publications (3)

Publication Number Publication Date
JP2018531961A JP2018531961A (ja) 2018-11-01
JP2018531961A5 JP2018531961A5 (OSRAM) 2019-12-05
JP6889493B2 true JP6889493B2 (ja) 2021-06-18

Family

ID=58631977

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018521382A Active JP6889493B2 (ja) 2015-10-26 2016-10-26 脳卒中からの回復のための方法および組成物

Country Status (5)

Country Link
EP (1) EP3368040B1 (OSRAM)
JP (1) JP6889493B2 (OSRAM)
KR (1) KR102891465B1 (OSRAM)
CN (1) CN108348524A (OSRAM)
WO (1) WO2017075013A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3692144A1 (en) 2017-10-05 2020-08-12 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of dux4
JP2022509271A (ja) * 2018-11-30 2022-01-20 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド 窒素含有ヘテロシクリル系化合物及びその組成物、製造方法並びに使用
JP7384341B1 (ja) 2023-07-07 2023-11-21 学校法人冬木学園 脳卒中患者の身体の痛みの改善を目的とするリハビリテーションの効果を予測するための方法、及び、システム

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608060B1 (en) 1996-12-18 2003-08-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US20040082509A1 (en) * 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
DE60319073T2 (de) * 2002-03-20 2009-02-05 Elan Pharma International Ltd. Nanopartikelzusammensetzungen von mitogen-aktivierten protein (map) kinase inhibitoren
WO2003084524A1 (en) * 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
EP2296653B1 (en) * 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
DK179584B1 (en) 2014-07-08 2019-02-20 Halliburton Energy Services REAL TIME CONFORMITY
US9579322B2 (en) * 2014-07-09 2017-02-28 Eip Pharma, Llc Methods for treating neurologic disorders

Also Published As

Publication number Publication date
CN108348524A (zh) 2018-07-31
WO2017075013A1 (en) 2017-05-04
EP3368040B1 (en) 2022-08-17
JP2018531961A (ja) 2018-11-01
EP3368040A1 (en) 2018-09-05
KR102891465B1 (ko) 2025-11-25
KR20180101322A (ko) 2018-09-12
EP3368040A4 (en) 2019-05-29

Similar Documents

Publication Publication Date Title
JP6861764B2 (ja) 軸索再生および神経機能を促進するための方法および組成物
ES2750728T3 (es) Uso de cannabinoides en combinación con Aripriprazol
CN106102737B (zh) 色甘酸衍生物以及成像和治疗的相关方法
TWI452039B (zh) 抗神經變性疾病用劑
JP6660369B2 (ja) 神経障害を治療する方法
KR102293847B1 (ko) 근위축성 측색 경화증 환자 아집단의 치료를 위한 마시티닙의 용도
JP2010531879A (ja) 水素化ピリド［４，３−ｂ］インドールに基づく抗不安作用を示す薬物、その薬理学的な化合物および適用方法
KR20100024951A (ko) 세포를 자극하기 위한 방법 및 조성물
AU2016215035A1 (en) Compounds and uses in treatment of senescence-associated conditions
JP6889493B2 (ja) 脳卒中からの回復のための方法および組成物
Dong et al. Protective effect of HIF-1α against hippocampal apoptosis and cognitive dysfunction in an experimental rat model of subarachnoid hemorrhage
TW200916101A (en) Telomerase activating compounds and methods of use thereof
CA3058967A1 (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
WO2009155777A1 (zh) 法舒地尔化合物的用途、方法及其药物组合物
US9427439B1 (en) Methods and compositions for recovery from stroke
CN108472332B (zh) 用于通过经鼻施用来治疗中风的组合物
ES2935705T3 (es) Un ligando del receptor GABA A
JPWO2003024446A1 (ja) 酸化ストレス抑制剤および酸化ストレスの測定方法
JP6606298B2 (ja) 純粋な５−ｈｔ６受容体アンタゴニストのｎｍｄａ受容体アンタゴニストとの組合せ
JP2021504462A (ja) トロポミオシン受容体キナーゼａ（ｔｒｋａ）阻害剤としてのピリミジン誘導体
JP7399284B2 (ja) 脳卒中または脳卒中による後遺症治療のためのシルデナフィル及びｒｏｃｋ阻害剤の用途
CN110799189A (zh) 纯5-ht6受体拮抗剂的新用途
Hosseini et al. Photothrombotically induced unilateral selective hippocampal ischemia in rat
JP5469707B2 (ja) 脳梗塞に関連する脳血管障害の治療に有用なピラゾロン化合物
JP2024153742A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210326

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210510

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210514

R150 Certificate of patent or registration of utility model

Ref document number: 6889493

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250